How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/triptorelin-recombinant-lh.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

triptorelin, recombinant LH — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

triptorelin, recombinant LH (triptorelin, recombinant LH) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist with recombinant LH supplementation. Area: Reproductive Medicine / Fertility.

marketed GnRH agonist with recombinant LH supplementation GnRH receptor; LH receptor Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

triptorelin, recombinant LH (triptorelin, recombinant LH) — IVI Madrid. Triptorelin is a GnRH agonist that stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to support reproductive function.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
triptorelin, recombinant LH TARGET	triptorelin, recombinant LH	IVI Madrid	marketed	GnRH agonist with recombinant LH supplementation	GnRH receptor; LH receptor
GnRh agonist +1500E hCG	GnRh agonist +1500E hCG	AZ Jan Palfijn Gent	marketed	GnRH agonist with hCG supplementation	GnRH receptor; LH receptor (via hCG)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GnRH agonist with recombinant LH supplementation class)

IVI Madrid · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). triptorelin, recombinant LH — Competitive Intelligence Brief. https://druglandscape.com/ci/triptorelin-recombinant-lh. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing